The FDA has approved a drug developed by Novartis for the treatment of the most common form of skin cancer. Odomzo was green-lighted for treatment of advanced basal cell carcinoma.
The FDA has approved a drug developed by Novartis for the treatment of the most common form of skin cancer. Odomzo was green-lighted for treatment of advanced basal cell carcinoma.
Share this Article
Recommended